Skip to main content

Advertisement

Table 1 Clinical characteristics of the DLBCL patients and univariate analysis for predictors of PFS and OS in the training and validation cohort

From: MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Characteristics Training cohort (n = 60) Validation cohort (n = 140) P value Training cohort Validation cohort
P value for PFS P value for OS P value for PFS P value for OS
Age
>  60 years 26/60 (43.3%) 49/140 (35.0%) 0.265 0.026 0.045 0.075 0.028
≤60 years 34/60 (56.7%) 91/140 (65.0%)      
Sex
Female 24/60 (40.0%) 56/140 (40.0%) 1.000 0.261 0.541 0.396 0.918
Male 36/60 (60.0%) 84/140 (60.0%)      
Performance status (ECOG)
0–1 51/60 (85.0%) 119/140 (85.0%) 1.000 0.100 0.048 < 0.001 0.210
2 9/60 (15.0%) 23/140 (15.0%)      
Lactic dehydrogenase
Normal 37/60 (61.7%) 81/140 (57.9%) 0.616 0.045 0.113 < 0.001 0.011
Elevated 23/60 (38.3%) 59/140 (42.1%)      
Ann Arbor stage
I-II 25/60 (41.7%) 72/140 (51.4%) 0.206 0.003 0.010 0.020 0.081
III-IV 35/60 (58.3%) 68/140 (48.6%)      
Extranodal involvement
Yes 20/60 (33.3%) 33/140 (23.6%) 0.165 < 0.001 < 0.001 0.988 0.918
No 40/60 (66.7%) 107/140 (76.4%)      
Revised International Prognostic Index (R-IPI)
Very good 10/60 (16.7%) 39/140 (27.9%) 0.230 < 0.001 0.001 0.013 0.323
Good 31/60 (51.7%) 60/140 (42.9%)      
Poor 19/60 (31.7%) 41/140 (29.3%)      
MiR155
Low 31/60 (51.7%) 69/140 (49.3%) 0.758 0.012 0.015 0.022 0.021
High 29/60 (48.3%) 71/140 (50.7%)